STARLI / TEN-FLAGSHIP RESEARCH CONSTELLATION YULI · NANO × QUANTUM × REGENERATION × AI × BCI F021–F025 / 200 | Family 03: Nanomedicine for Neural Repair F021 Neural-Targeted Nanocarriers at the Limit Core: receptor binding × intracellular cargo delivery × independently measured off-target exposure. Endpoint: target-cell uptake fraction [percent]. Hidden challenge: concealed receptor-blocking ligand. Rival: surface adsorption or fluorescent dye leakage. F022 Blood–Brain Barrier Nanodelivery Engineering at the Limit Core: endothelial junction integrity × transcellular transport × independent receiver mass balance. Endpoint: apparent permeability coefficient [meter per second]. Hidden challenge: ligand blocking without cell loss. Rival: barrier leakage or dye-only passage. F023 Controlled Nanorelease of Neural Regenerative Factors at the Limit Core: polymer degradation × molecular potency × time-resolved exposure control. Endpoint: released active factor fraction [percent]. Hidden challenge: blind membrane thickness exchange. Rival: assay-detected inactive fragments or burst-only delivery. F024 Nanomodulation of Neuroinflammatory Microenvironments at the Limit Core: cargo exposure × immune phenotype × orthogonal viability-adjusted cytokine readout. Endpoint: viability-adjusted cytokine concentration [picogram per milliliter]. Hidden challenge: cell-density blinded uptake pulse. Rival: cytokine assay interference or depletion of surviving immune cells. F025 Extracellular Vesicle Nanodelivery for Neural Repair at the Limit Core: vesicle membrane identity × protected cargo transfer × cell-specific uptake witness. Endpoint: intact cargo recovery fraction [percent]. Hidden challenge: masked vesicle-surface protease control. Rival: co-isolated free biomolecule or residual dye. FIRST-PRINCIPLES EVIDENCE CONTRACT Ten prospective English research books, each 777 pages with 30 formulas, 82 chapters, 410 single-page studies, 200 Gates with three future-letter passages, and 33 Phoenix. Drug-carrier uptake, barrier passage, intact active cargo and neural functional recovery are distinct propositions. The F02 PDF transfers independent verification rules by analogy; it does not establish nanotherapeutic efficacy. STARLI / TEN-FLAGSHIP RESEARCH CONSTELLATION YULI · NANO × QUANTUM × REGENERATION × AI × BCI F026–F030 / 200 | Family 03: Nanomedicine for Neural Repair F026 Intelligent Neural Nanopharmacokinetics at the Limit Core: time-resolved exposure × compartment clearance × model identifiability. Endpoint: target-compartment exposure AUC [milligram hour per liter]. Hidden challenge: concealed redistribution-rate crossover. Rival: unobserved protein binding or biased sampling volume. F027 Neural Targeting and Off-Target Risk at the Limit Core: target delivery × peripheral exposure × harm-sensitive selectivity. Endpoint: target-to-offtarget concentration ratio [dimensionless]. Hidden challenge: hidden cross-reactive receptor expression. Rival: apparent targeting from omitted off-target compartments. F028 Stimuli-Responsive Neural Nanocarriers at the Limit Core: trigger specificity × reversible activation × bounded cargo exposure. Endpoint: triggered-to-background release ratio [dimensionless]. Hidden challenge: concealed thermal sham at identical dose. Rival: thermal, osmotic or chemical leakage masquerading as trigger action. F029 Batch Consistency of Neural Repair Nanoformulations at the Limit Core: particle-size dispersion × cargo potency × independent lot qualification. Endpoint: particle diameter coefficient of variation [percent]. Hidden challenge: masked mixing speed trial. Rival: selective exclusion of failed batches or analyzer drift. F030 Evidence Translation for Neural Nanotherapeutics at the Limit Core: preclinical construct validity × second-site replication × transparent translation limits. Endpoint: external-to-internal effect ratio [dimensionless]. Hidden challenge: independent endpoint relabeling audit. Rival: selection bias or endpoint drift across studies. VERIFIED EXTERNAL SOURCES AND LIMITS Published method context: Gao et al., DOI 10.1038/s41578-024-00695-w; Odom et al., DOI 10.1039/D3NR06154J; Teixeira et al., DOI 10.1016/j.actbio.2024.09.027; Zhou et al., DOI 10.3390/ph15030358. Nonclinical research designs only; no completed efficacy experiments, clinical claims, or expert scientific clearance. Join the STARLI Research Community · https://zenodo.org/communities/starli-research-gate/ We do not need to know which door future generations will choose to open. We only hope that when they open it, they will find a little light to guide their way. 🌈🚪✨

BibTeX

@article{allodium:10.5281/zenodo.23965702,
  title = {STARLI / TEN-FLAGSHIP RESEARCH CONSTELLATION YULI · NANO × QUANTUM × REGENERATION × AI × BCI F021–F025 / 200  |  Family 03: Nanomedicine for Neural Repair F021  Neural-Targeted Nanocarriers at the Limit Core: receptor binding × intracellular cargo delivery × independently measured off-target exposure. Endpoint: target-cell uptake fraction [percent]. Hidden challenge: concealed receptor-blocking ligand. Rival: surface adsorption or fluorescent dye leakage. F022  Blood–Brain Barrier Nanodelivery Engineering at the Limit Core: endothelial junction integrity × transcellular transport × independent receiver mass balance. Endpoint: apparent permeability coefficient [meter per second]. Hidden challenge: ligand blocking without cell loss. Rival: barrier leakage or dye-only passage. F023  Controlled Nanorelease of Neural Regenerative Factors at the Limit Core: polymer degradation × molecular potency × time-resolved exposure control. Endpoint: released active factor fraction [percent]. Hidden challenge: blind membrane thickness exchange. Rival: assay-detected inactive fragments or burst-only delivery. F024  Nanomodulation of Neuroinflammatory Microenvironments at the Limit Core: cargo exposure × immune phenotype × orthogonal viability-adjusted cytokine readout. Endpoint: viability-adjusted cytokine concentration [picogram per milliliter]. Hidden challenge: cell-density blinded uptake pulse. Rival: cytokine assay interference or depletion of surviving immune cells. F025  Extracellular Vesicle Nanodelivery for Neural Repair at the Limit Core: vesicle membrane identity × protected cargo transfer × cell-specific uptake witness. Endpoint: intact cargo recovery fraction [percent]. Hidden challenge: masked vesicle-surface protease control. Rival: co-isolated free biomolecule or residual dye. FIRST-PRINCIPLES EVIDENCE CONTRACT Ten prospective English research books, each 777 pages with 30 formulas, 82 chapters, 410 single-page studies, 200 Gates with three future-letter passages, and 33 Phoenix. Drug-carrier uptake, barrier passage, intact active cargo and neural functional recovery are distinct propositions. The F02 PDF transfers independent verification rules by analogy; it does not establish nanotherapeutic efficacy.  STARLI / TEN-FLAGSHIP RESEARCH CONSTELLATION YULI · NANO × QUANTUM × REGENERATION × AI × BCI F026–F030 / 200  |  Family 03: Nanomedicine for Neural Repair F026  Intelligent Neural Nanopharmacokinetics at the Limit Core: time-resolved exposure × compartment clearance × model identifiability. Endpoint: target-compartment exposure AUC [milligram hour per liter]. Hidden challenge: concealed redistribution-rate crossover. Rival: unobserved protein binding or biased sampling volume. F027  Neural Targeting and Off-Target Risk at the Limit Core: target delivery × peripheral exposure × harm-sensitive selectivity. Endpoint: target-to-offtarget concentration ratio [dimensionless]. Hidden challenge: hidden cross-reactive receptor expression. Rival: apparent targeting from omitted off-target compartments. F028  Stimuli-Responsive Neural Nanocarriers at the Limit Core: trigger specificity × reversible activation × bounded cargo exposure. Endpoint: triggered-to-background release ratio [dimensionless]. Hidden challenge: concealed thermal sham at identical dose. Rival: thermal, osmotic or chemical leakage masquerading as trigger action. F029  Batch Consistency of Neural Repair Nanoformulations at the Limit Core: particle-size dispersion × cargo potency × independent lot qualification. Endpoint: particle diameter coefficient of variation [percent]. Hidden challenge: masked mixing speed trial. Rival: selective exclusion of failed batches or analyzer drift. F030  Evidence Translation for Neural Nanotherapeutics at the Limit Core: preclinical construct validity × second-site replication × transparent translation limits. Endpoint: external-to-internal effect ratio [dimensionless]. Hidden challenge: independent endpoint relabeling audit. Rival: selection bias or endpoint drift across studies. VERIFIED EXTERNAL SOURCES AND LIMITS Published method context: Gao et al., DOI 10.1038/s41578-024-00695-w; Odom et al., DOI 10.1039/D3NR06154J; Teixeira et al., DOI 10.1016/j.actbio.2024.09.027; Zhou et al., DOI 10.3390/ph15030358. Nonclinical research designs only; no completed efficacy experiments, clinical claims, or expert scientific clearance. Join the STARLI Research Community · https://zenodo.org/communities/starli-research-gate/ We do not need to know which door future generations will choose to open. We only hope that when they open it, they will find a little light to guide their way. 🌈🚪✨},
  author = {33},
  year = {2026},
  doi = {10.5281/zenodo.23965702},
  url = {https://doi.org/10.5281/zenodo.23965702}
}

RIS

TY  - JOUR
TI  - STARLI / TEN-FLAGSHIP RESEARCH CONSTELLATION YULI · NANO × QUANTUM × REGENERATION × AI × BCI F021–F025 / 200  |  Family 03: Nanomedicine for Neural Repair F021  Neural-Targeted Nanocarriers at the Limit Core: receptor binding × intracellular cargo delivery × independently measured off-target exposure. Endpoint: target-cell uptake fraction [percent]. Hidden challenge: concealed receptor-blocking ligand. Rival: surface adsorption or fluorescent dye leakage. F022  Blood–Brain Barrier Nanodelivery Engineering at the Limit Core: endothelial junction integrity × transcellular transport × independent receiver mass balance. Endpoint: apparent permeability coefficient [meter per second]. Hidden challenge: ligand blocking without cell loss. Rival: barrier leakage or dye-only passage. F023  Controlled Nanorelease of Neural Regenerative Factors at the Limit Core: polymer degradation × molecular potency × time-resolved exposure control. Endpoint: released active factor fraction [percent]. Hidden challenge: blind membrane thickness exchange. Rival: assay-detected inactive fragments or burst-only delivery. F024  Nanomodulation of Neuroinflammatory Microenvironments at the Limit Core: cargo exposure × immune phenotype × orthogonal viability-adjusted cytokine readout. Endpoint: viability-adjusted cytokine concentration [picogram per milliliter]. Hidden challenge: cell-density blinded uptake pulse. Rival: cytokine assay interference or depletion of surviving immune cells. F025  Extracellular Vesicle Nanodelivery for Neural Repair at the Limit Core: vesicle membrane identity × protected cargo transfer × cell-specific uptake witness. Endpoint: intact cargo recovery fraction [percent]. Hidden challenge: masked vesicle-surface protease control. Rival: co-isolated free biomolecule or residual dye. FIRST-PRINCIPLES EVIDENCE CONTRACT Ten prospective English research books, each 777 pages with 30 formulas, 82 chapters, 410 single-page studies, 200 Gates with three future-letter passages, and 33 Phoenix. Drug-carrier uptake, barrier passage, intact active cargo and neural functional recovery are distinct propositions. The F02 PDF transfers independent verification rules by analogy; it does not establish nanotherapeutic efficacy.  STARLI / TEN-FLAGSHIP RESEARCH CONSTELLATION YULI · NANO × QUANTUM × REGENERATION × AI × BCI F026–F030 / 200  |  Family 03: Nanomedicine for Neural Repair F026  Intelligent Neural Nanopharmacokinetics at the Limit Core: time-resolved exposure × compartment clearance × model identifiability. Endpoint: target-compartment exposure AUC [milligram hour per liter]. Hidden challenge: concealed redistribution-rate crossover. Rival: unobserved protein binding or biased sampling volume. F027  Neural Targeting and Off-Target Risk at the Limit Core: target delivery × peripheral exposure × harm-sensitive selectivity. Endpoint: target-to-offtarget concentration ratio [dimensionless]. Hidden challenge: hidden cross-reactive receptor expression. Rival: apparent targeting from omitted off-target compartments. F028  Stimuli-Responsive Neural Nanocarriers at the Limit Core: trigger specificity × reversible activation × bounded cargo exposure. Endpoint: triggered-to-background release ratio [dimensionless]. Hidden challenge: concealed thermal sham at identical dose. Rival: thermal, osmotic or chemical leakage masquerading as trigger action. F029  Batch Consistency of Neural Repair Nanoformulations at the Limit Core: particle-size dispersion × cargo potency × independent lot qualification. Endpoint: particle diameter coefficient of variation [percent]. Hidden challenge: masked mixing speed trial. Rival: selective exclusion of failed batches or analyzer drift. F030  Evidence Translation for Neural Nanotherapeutics at the Limit Core: preclinical construct validity × second-site replication × transparent translation limits. Endpoint: external-to-internal effect ratio [dimensionless]. Hidden challenge: independent endpoint relabeling audit. Rival: selection bias or endpoint drift across studies. VERIFIED EXTERNAL SOURCES AND LIMITS Published method context: Gao et al., DOI 10.1038/s41578-024-00695-w; Odom et al., DOI 10.1039/D3NR06154J; Teixeira et al., DOI 10.1016/j.actbio.2024.09.027; Zhou et al., DOI 10.3390/ph15030358. Nonclinical research designs only; no completed efficacy experiments, clinical claims, or expert scientific clearance. Join the STARLI Research Community · https://zenodo.org/communities/starli-research-gate/ We do not need to know which door future generations will choose to open. We only hope that when they open it, they will find a little light to guide their way. 🌈🚪✨
AU  - 33
PY  - 2026
DO  - 10.5281/zenodo.23965702
UR  - https://doi.org/10.5281/zenodo.23965702
ER  - 

APA

33 (2026). STARLI / TEN-FLAGSHIP RESEARCH CONSTELLATION YULI · NANO × QUANTUM × REGENERATION × AI × BCI F021–F025 / 200 | Family 03: Nanomedicine for Neural Repair F021 Neural-Targeted Nanocarriers at the Limit Core: receptor binding × intracellular cargo delivery × independently measured off-target exposure. Endpoint: target-cell uptake fraction [percent]. Hidden challenge: concealed receptor-blocking ligand. Rival: surface adsorption or fluorescent dye leakage. F022 Blood–Brain Barrier Nanodelivery Engineering at the Limit Core: endothelial junction integrity × transcellular transport × independent receiver mass balance. Endpoint: apparent permeability coefficient [meter per second]. Hidden challenge: ligand blocking without cell loss. Rival: barrier leakage or dye-only passage. F023 Controlled Nanorelease of Neural Regenerative Factors at the Limit Core: polymer degradation × molecular potency × time-resolved exposure control. Endpoint: released active factor fraction [percent]. Hidden challenge: blind membrane thickness exchange. Rival: assay-detected inactive fragments or burst-only delivery. F024 Nanomodulation of Neuroinflammatory Microenvironments at the Limit Core: cargo exposure × immune phenotype × orthogonal viability-adjusted cytokine readout. Endpoint: viability-adjusted cytokine concentration [picogram per milliliter]. Hidden challenge: cell-density blinded uptake pulse. Rival: cytokine assay interference or depletion of surviving immune cells. F025 Extracellular Vesicle Nanodelivery for Neural Repair at the Limit Core: vesicle membrane identity × protected cargo transfer × cell-specific uptake witness. Endpoint: intact cargo recovery fraction [percent]. Hidden challenge: masked vesicle-surface protease control. Rival: co-isolated free biomolecule or residual dye. FIRST-PRINCIPLES EVIDENCE CONTRACT Ten prospective English research books, each 777 pages with 30 formulas, 82 chapters, 410 single-page studies, 200 Gates with three future-letter passages, and 33 Phoenix. Drug-carrier uptake, barrier passage, intact active cargo and neural functional recovery are distinct propositions. The F02 PDF transfers independent verification rules by analogy; it does not establish nanotherapeutic efficacy. STARLI / TEN-FLAGSHIP RESEARCH CONSTELLATION YULI · NANO × QUANTUM × REGENERATION × AI × BCI F026–F030 / 200 | Family 03: Nanomedicine for Neural Repair F026 Intelligent Neural Nanopharmacokinetics at the Limit Core: time-resolved exposure × compartment clearance × model identifiability. Endpoint: target-compartment exposure AUC [milligram hour per liter]. Hidden challenge: concealed redistribution-rate crossover. Rival: unobserved protein binding or biased sampling volume. F027 Neural Targeting and Off-Target Risk at the Limit Core: target delivery × peripheral exposure × harm-sensitive selectivity. Endpoint: target-to-offtarget concentration ratio [dimensionless]. Hidden challenge: hidden cross-reactive receptor expression. Rival: apparent targeting from omitted off-target compartments. F028 Stimuli-Responsive Neural Nanocarriers at the Limit Core: trigger specificity × reversible activation × bounded cargo exposure. Endpoint: triggered-to-background release ratio [dimensionless]. Hidden challenge: concealed thermal sham at identical dose. Rival: thermal, osmotic or chemical leakage masquerading as trigger action. F029 Batch Consistency of Neural Repair Nanoformulations at the Limit Core: particle-size dispersion × cargo potency × independent lot qualification. Endpoint: particle diameter coefficient of variation [percent]. Hidden challenge: masked mixing speed trial. Rival: selective exclusion of failed batches or analyzer drift. F030 Evidence Translation for Neural Nanotherapeutics at the Limit Core: preclinical construct validity × second-site replication × transparent translation limits. Endpoint: external-to-internal effect ratio [dimensionless]. Hidden challenge: independent endpoint relabeling audit. Rival: selection bias or endpoint drift across studies. VERIFIED EXTERNAL SOURCES AND LIMITS Published method context: Gao et al., DOI 10.1038/s41578-024-00695-w; Odom et al., DOI 10.1039/D3NR06154J; Teixeira et al., DOI 10.1016/j.actbio.2024.09.027; Zhou et al., DOI 10.3390/ph15030358. Nonclinical research designs only; no completed efficacy experiments, clinical claims, or expert scientific clearance. Join the STARLI Research Community · https://zenodo.org/communities/starli-research-gate/ We do not need to know which door future generations will choose to open. We only hope that when they open it, they will find a little light to guide their way. 🌈🚪✨. https://doi.org/10.5281/zenodo.23965702